Dendritic cells pulsed with peptides from prostate-specific membrane antigen data

CYTO’s PSMA-based immunotherapy has provided a long-term immune effect in responders from a Phase I trial, as shown

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE